A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with CLL who are Intolerant to Prior BTK or PI3K Inhibitor Therapy

Drug Category : Array
Conference Category : Array
Lead Author : Mato A, et al.
Published Date : 04/06/2018
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2025/09/Final-2018-TKI-ASCO.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top